These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19782286)

  • 1. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.
    Ranganathan K; Worley S; Michaels MG; Arrigan S; Aurora P; Ballmann M; Boyer D; Conrad C; Eichler I; Elidemir O; Goldfarb S; Mallory GB; Mogayzel PJ; Parakininkas D; Solomon M; Visner G; Sweet SC; Faro A; Danziger-Isakov L
    J Heart Lung Transplant; 2009 Oct; 28(10):1050-6. PubMed ID: 19782286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
    Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
    Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
    Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.
    Valantine HA; Luikart H; Doyle R; Theodore J; Hunt S; Oyer P; Robbins R; Berry G; Reitz B
    Transplantation; 2001 Nov; 72(10):1647-52. PubMed ID: 11726825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.
    Kruger RM; Paranjothi S; Storch GA; Lynch JP; Trulock EP
    J Heart Lung Transplant; 2003 Jul; 22(7):754-63. PubMed ID: 12873543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation.
    Rea F; Potena L; Yonan N; Wagner F; Calabrese F
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S19-26. PubMed ID: 26900991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases.
    Nagai S; Mangus RS; Anderson E; Ekser B; Kubal CA; Fridell JA; Tector AJ
    Transplantation; 2016 Feb; 100(2):451-60. PubMed ID: 26247555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients.
    Kocher AA; Bonaros N; Dunkler D; Ehrlich M; Schlechta B; Zweytick B; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2003 Mar; 22(3):250-7. PubMed ID: 12633691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
    Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
    Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation.
    Danziger-Isakov LA; Worley S; Michaels MG; Arrigain S; Aurora P; Ballmann M; Boyer D; Conrad C; Eichler I; Elidemir O; Goldfarb S; Mallory GB; Mogayzel PJ; Parakininkas D; Solomon M; Visner G; Sweet S; Faro A
    Transplantation; 2009 May; 87(10):1541-8. PubMed ID: 19461492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
    Johansson I; Mårtensson G; Nyström U; Nasic S; Andersson R
    BMC Infect Dis; 2013 Dec; 13():582. PubMed ID: 24325216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction.
    Weill D; Lock BJ; Wewers DL; Young KR; Zorn GL; Early L; Kirklin JK; McGiffin DC
    Am J Transplant; 2003 Apr; 3(4):492-6. PubMed ID: 12694074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation.
    Zamora MR
    Transpl Infect Dis; 2001; 3 Suppl 2():49-56. PubMed ID: 11926751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
    Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients.
    Snydman DR; Kistler KD; Ulsh P; Morris J
    Transplantation; 2010 Dec; 90(12):1432-8. PubMed ID: 21076378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial.
    Snydman DR; Werner BG; Dougherty NN; Griffith J; Rubin RH; Dienstag JL; Rohrer RH; Freeman R; Jenkins R; Lewis WD; Hammer S; O'Rourke E; Grady GF; Fawaz K; Kaplan MM; Hoffman MA; Katz AT; Doran M;
    Ann Intern Med; 1993 Nov; 119(10):984-91. PubMed ID: 8214995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.